These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 25327503)

  • 1. The impact of missing data on the results of a schizophrenia study.
    Rybin D; Doros G; Rosenheck R; Lew R
    Pharm Stat; 2015; 14(1):4-10. PubMed ID: 25327503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences in treatment effect among clinical subgroups in a randomized clinical trial of long-acting injectable risperidone and oral antipsychotics in unstable chronic schizophrenia.
    Leatherman SM; Liang MH; Krystal JH; Lew RA; Valley D; Thwin SS; Rosenheck RA;
    J Nerv Ment Dis; 2014 Jan; 202(1):13-7. PubMed ID: 24375206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcomes of long-acting risperidone in recent versus long-term diagnosed Belgian schizophrenic patients: results from electronic Schizophrenia Treatment Adherence Registry (e-STAR) and Trial for the Initiation and Maintenance Of REmission in Schizophrenia with risperidone (TIMORES).
    Dubois V; Peuskens J; Geerts P; Detraux J
    Early Interv Psychiatry; 2014 Feb; 8(1):39-49. PubMed ID: 23343330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-acting risperidone and oral antipsychotics in unstable schizophrenia.
    Rosenheck RA; Krystal JH; Lew R; Barnett PG; Fiore L; Valley D; Thwin SS; Vertrees JE; Liang MH;
    N Engl J Med; 2011 Mar; 364(9):842-51. PubMed ID: 21366475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges in the design and conduct of controlled clinical effectiveness trials in schizophrenia.
    Rosenheck RA; Krystal JH; Lew R; Barnett PG; Thwin SS; Fiore L; Valley D; Huang GD; Neal C; Vertrees JE; Liang MH;
    Clin Trials; 2011 Apr; 8(2):196-204. PubMed ID: 21270143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Long-acting injectable risperidone: naturalistic study in three hospitals in Aquitaine].
    Raignoux C; Dusouchet T; Bret P; Queuille E; Biscay ML; Caron J; Bret MC
    Encephale; 2007 Dec; 33(6):973-81. PubMed ID: 18789790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome.
    Weiden PJ; Schooler NR; Weedon JC; Elmouchtari A; Sunakawa A; Goldfinger SM
    J Clin Psychiatry; 2009 Oct; 70(10):1397-406. PubMed ID: 19906343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-acting injectable risperidone.
    Ehret MJ; Fuller MA
    Ann Pharmacother; 2004 Dec; 38(12):2122-7. PubMed ID: 15522979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia.
    Barnett PG; Scott JY; Krystal JH; Rosenheck RA;
    J Clin Psychiatry; 2012 May; 73(5):696-702. PubMed ID: 22697193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical review of a long-acting, injectable formulation of risperidone.
    Knox ED; Stimmel GL
    Clin Ther; 2004 Dec; 26(12):1994-2002. PubMed ID: 15823763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Bayesian framework to account for uncertainty due to missing binary outcome data in pairwise meta-analysis.
    Turner NL; Dias S; Ades AE; Welton NJ
    Stat Med; 2015 May; 34(12):2062-80. PubMed ID: 25809313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
    Houthoofd SA; Morrens M; Sabbe BG
    Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea.
    Lee NY; Kim SH; Cho SJ; Chung YC; Jung IK; Kim CY; Kim DH; Lee DG; Lee YH; Lim WJ; Na YS; Shin SE; Woo JM; Yoon JS; Yoon BH; Ahn YM; Kim YS
    Int Clin Psychopharmacol; 2014 Sep; 29(5):279-87. PubMed ID: 24583566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of health services use following the initiation of risperidone long-acting therapy among schizophrenia patients in the veterans health administration.
    Ren XS; Crivera C; Sikirica M; Dirani R; Qian S; Kazis LE
    J Clin Pharm Ther; 2011 Jun; 36(3):383-9. PubMed ID: 21062329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accounting for uncertainty due to 'last observation carried forward' outcome imputation in a meta-analysis model.
    Dimitrakopoulou V; Efthimiou O; Leucht S; Salanti G
    Stat Med; 2015 Feb; 34(5):742-52. PubMed ID: 25492741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimens.
    Fu DJ; Bossie CA; Kern Sliwa J; Ma YW; Alphs L
    Clin Schizophr Relat Psychoses; 2014 Jul; 8(2):101-9, 109A. PubMed ID: 23446197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
    Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
    J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical experience with the long-acting injectable formulation of the atypical antipsychotic, risperidone.
    Martin SD; Libretto SE; Pratt DJ; Brewin JS; Huq ZU; Saleh BT
    Curr Med Res Opin; 2003; 19(4):298-305. PubMed ID: 12841922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risperidone: an analysis of the first three years in general use.
    Gutierrez-Esteinou R; Grebb JA
    Int Clin Psychopharmacol; 1997 Sep; 12 Suppl 4():S3-10. PubMed ID: 9352340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.